BR112022014925A8 - Inibidores macrocíclicos de rip2-quinase - Google Patents
Inibidores macrocíclicos de rip2-quinaseInfo
- Publication number
- BR112022014925A8 BR112022014925A8 BR112022014925A BR112022014925A BR112022014925A8 BR 112022014925 A8 BR112022014925 A8 BR 112022014925A8 BR 112022014925 A BR112022014925 A BR 112022014925A BR 112022014925 A BR112022014925 A BR 112022014925A BR 112022014925 A8 BR112022014925 A8 BR 112022014925A8
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- rip2
- macrocyclic
- compounds
- kinase
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
INIBIDORES MACROCÍCLICOS DE RIP2-QUINASE. A presente invenção refere-se a compostos macrocíclicos e a composições contendo os ditos compostos que atuam como inibidores de quinase, em particular como inibidores de RIP2-quinase, e/ou mutantes da mesma, para uso no diagnóstico, na prevenção e/ou no tratamento de doenças associadas à RIP2-quinase. Além disso, a presente invenção refere-se a métodos de uso dos ditos compostos, por exemplo, como medicamento ou agente de diagnóstico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20154852.6 | 2020-01-31 | ||
| EP20154852 | 2020-01-31 | ||
| PCT/EP2021/052255 WO2021152165A1 (en) | 2020-01-31 | 2021-02-01 | Macrocyclic rip2-kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112022014925A2 BR112022014925A2 (pt) | 2022-09-20 |
| BR112022014925A8 true BR112022014925A8 (pt) | 2023-05-09 |
| BR112022014925B1 BR112022014925B1 (pt) | 2023-12-19 |
Family
ID=69423151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014925-5A BR112022014925B1 (pt) | 2020-01-31 | 2021-02-01 | Inibidores macrocíclicos de rip2-quinase, seus usos, e composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230126352A1 (pt) |
| EP (1) | EP4097110A1 (pt) |
| JP (1) | JP2023516551A (pt) |
| KR (1) | KR20230005117A (pt) |
| CN (1) | CN115698020A (pt) |
| AR (1) | AR124556A1 (pt) |
| AU (1) | AU2021214866A1 (pt) |
| BR (1) | BR112022014925B1 (pt) |
| CA (1) | CA3168814A1 (pt) |
| IL (1) | IL295196A (pt) |
| MX (1) | MX2022009285A (pt) |
| TW (1) | TW202140499A (pt) |
| UY (1) | UY39061A (pt) |
| WO (1) | WO2021152165A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114874221A (zh) * | 2022-05-12 | 2022-08-09 | 广州佳途科技股份有限公司 | 一种rip2激酶抑制剂中间体及其合成方法 |
| WO2024099363A1 (zh) * | 2022-11-09 | 2024-05-16 | 宁波康柏睿格医药科技有限公司 | Rip2抑制剂联合免疫检查点抑制剂药物组合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150129016A (ko) * | 2013-03-15 | 2015-11-18 | 입센 파마 에스.에이.에스 | 마크로시클릭 lrrk2 키나제 억제제 |
| BR112015022650A8 (pt) * | 2013-03-15 | 2018-01-23 | Oncodesign Sa | inibidores de quinase induzível por sal macrocíclico. |
| MX2015012526A (es) * | 2013-03-15 | 2016-04-26 | Oncodesign Sa | Inhibodores macrociclicos de cinasa rip2. |
| WO2015136073A1 (en) * | 2014-03-14 | 2015-09-17 | Oncodesign Sa | Macrocyclic tgf-br2 kinase inhibitors |
| CN107108641A (zh) * | 2014-09-17 | 2017-08-29 | 昂科迪塞恩股份有限公司 | 大环lrrk2激酶抑制剂 |
| WO2016042087A1 (en) | 2014-09-17 | 2016-03-24 | Oncodesign S.A. | Macrocyclic rip2 kinase inhibitors |
-
2021
- 2021-02-01 CA CA3168814A patent/CA3168814A1/en active Pending
- 2021-02-01 TW TW110103705A patent/TW202140499A/zh unknown
- 2021-02-01 AU AU2021214866A patent/AU2021214866A1/en active Pending
- 2021-02-01 AR ARP210100265A patent/AR124556A1/es unknown
- 2021-02-01 KR KR1020227028996A patent/KR20230005117A/ko active Search and Examination
- 2021-02-01 CN CN202180023037.4A patent/CN115698020A/zh active Pending
- 2021-02-01 UY UY0001039061A patent/UY39061A/es unknown
- 2021-02-01 US US17/759,644 patent/US20230126352A1/en active Pending
- 2021-02-01 JP JP2022546542A patent/JP2023516551A/ja active Pending
- 2021-02-01 MX MX2022009285A patent/MX2022009285A/es unknown
- 2021-02-01 EP EP21702985.9A patent/EP4097110A1/en active Pending
- 2021-02-01 BR BR112022014925-5A patent/BR112022014925B1/pt active IP Right Grant
- 2021-02-01 WO PCT/EP2021/052255 patent/WO2021152165A1/en active Application Filing
- 2021-02-01 IL IL295196A patent/IL295196A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022014925A2 (pt) | 2022-09-20 |
| TW202140499A (zh) | 2021-11-01 |
| AU2021214866A1 (en) | 2022-09-22 |
| CA3168814A1 (en) | 2021-08-05 |
| WO2021152165A1 (en) | 2021-08-05 |
| IL295196A (en) | 2022-09-01 |
| MX2022009285A (es) | 2022-11-09 |
| JP2023516551A (ja) | 2023-04-20 |
| UY39061A (es) | 2022-01-31 |
| AR124556A1 (es) | 2023-04-12 |
| BR112022014925B1 (pt) | 2023-12-19 |
| EP4097110A1 (en) | 2022-12-07 |
| CN115698020A (zh) | 2023-02-03 |
| US20230126352A1 (en) | 2023-04-27 |
| KR20230005117A (ko) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| BR112022014925A8 (pt) | Inibidores macrocíclicos de rip2-quinase | |
| BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| BR112022010323A2 (pt) | Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal | |
| BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
| BR112018076485A8 (pt) | Carotenoides microbianos afetando a composição microbiana do intestino | |
| BR112017005299A2 (pt) | inibidores de lrrk2 cinase macrocíclicos | |
| BR112022025117A2 (pt) | 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BR112018012765A2 (pt) | composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico. | |
| BR112023025916A2 (pt) | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção | |
| BR112016026470A8 (pt) | composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto | |
| BR112017004035A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| BR112022014456A2 (pt) | Tafoxiparina para o tratamento da pré-eclâmpsia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ONCODESIGN PRECISION MEDICINE (OPM) (FR) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2021, OBSERVADAS AS CONDICOES LEGAIS |